What question did this study set out to answer?

The aim was to evaluate the effectiveness of darbepoetin alfa administered biweekly compared to rHuEPO for managing renal anemia.

February 9, 2026Journal of Nephrology

A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritone

View Full Paper

Ask AI

Bookmark

The aim was to evaluate the effectiveness of darbepoetin alfa administered biweekly compared to rHuEPO for managing renal anemia.
Single center, single arm study involving 17 patients on stable rHuEPO therapy.
Transitioned patients to darbepoetin alfa every other week using a 200:1 conversion factor.
Doses adjusted to maintain hemoglobin levels within specified ranges over 24 weeks.
Average hemoglobin change was 0.03 g/dL from baseline to evaluation period.
No significant or clinically relevant difference was found in hemoglobin levels.
No serious adverse effects were noted during the study.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Single-center trial examines darbepoetin alfa effects on anemia in patients on peritoneal dialysis, suggesting similar hemoglobin maintenance as rHuEPO.

Cite This Study

Mahajan et al. (2003) studied this question.

synapsesocial.com/papers/698979c8f0ec2af6756e7c29 https://doi.org/10.1093/joneph/17.5.687

View Full Paper

Ask AI

Bookmark

Implication

Single-center trial examines darbepoetin alfa effects on anemia in patients on peritoneal dialysis, suggesting similar hemoglobin maintenance as rHuEPO.

A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritone

Key Points

Discussion

Implication

Cite This Study

A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritone

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider